Official ESCRS | European Society of Cataract & Refractive Surgeons
Vienna 2018 Delegate Registration Programme Exhibition Virtual Exhibition Satellites 2018 Survey

 

escrs app advert

Visual performance following implantation of 4 presbyopia-correcting IOLs

Search Title by author or title

Session Details

Session Title: Pseudophakic IOLs: Multifocal

Venue:

First Author: : A.Hamid UK

Co Author(s): :                           

Abstract Details

Purpose:

To compare bilateral Symfony (EDOf) vs At Lisa Trifocal (Diffractive) vs FineVisionTrifocal (Diffractive) vs PanOptix Trifocal (Diffractive) Intraocular lenses

Setting:

Private Clinic Practice

Methods:

50 patents were implanted with the Symfony IOL, 50 patients were implanted with the At Lisa IOL, 50 Patients were implanted with the Physiol IOL and 50 the PanOptix IOL. FU at 1 week, 2, 3 & 6 months post op and the following parameters were measured: Monocular and binocular uncorrected distance, intermediate and near visual acuity. Photic phenomena rates and patient satisfaction.

Results:

UDVA was 1.01 +/- 0.16 in the Symfony vs 1.00 +/- 0.11 in the At Lisa group vs 0.95 +/-0.09 in the Physiol group and 1.00 +/-0.20 in the PanOptix Group. Intermediate vision was 0.9 +/- 0.21 vs 0.7 +/- 0.21 vs 0.85 +/- 0.15 vs 0.75 +/- .12 respectively. Near Vision was 0.6 +/-0.16 for the vs 0.71 +/- 0.21 vs 0.96 +/- 0.08 vs 0.72+/-0.20. 94.4 % of the Symfony group were spectacle independent at all distances vs 100% for both the the At Lisa/Physiol/PanOptix groups. The Symfony group had the highest level of patient satisfaction

Conclusions:

All 4 IOL produce excellent results with high levels of spectacle independence. The Symfony IOL produces better levels of distance and intermediate visual acuity. Physiol AT Lisa and PanOptix IOLs produced better near visual acuity. There is a higher frequency of dysphotopsia with the AT Lisa 839MP, PanOptix and FineVision IOLs. Dysphotopsia’s can contribute to patient dissatisfaction despite good spectacle independence

Financial Disclosure:

research is funded, fully or partially, by a company producing, developing or supplying the product or procedure presented

Back to previous